Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway

Journal article

CPIs have shown efficacy at first relapse, as salvage pre- and post-autologous (ASCT) and allogeneic stem cell transplant (alloSCT) and as maintenance post-ASCT. Immune-related adverse events require careful attention, especially when used peri-alloSCT, where it is associated with hyperacute graft-versus-host disease. Newer PD1 inhibitors, as well as strategies to overcome CPI resistance, are being tested. CPIs are increasingly deployed at earlier points in the classical Hodgkin lymphoma pathway. Whilst progress is clearly being made, randomised studies are required to more clearly define the optimal positioning of these agents.

Authors: Zhang, X-Y; Collins, GP

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer
• Journal: Current Oncology Reports
• Volume: 24
• Issue: 11
• Pages: 1477-1488
• Publication date: 2022-06-13
• DOI: 10.1007/s11912-022-01292-2
• EISSN: 1534-6269
• ISSN: 1523-3790
• Language: English
• Keywords: Medicine; Hodgkin lymphoma; Classical Hodgkin lymphoma; Internal medicine; Adverse effect; Lymphoma; Oncology; Refractory (planetary science); Salvage therapy; Chemotherapy; Brentuximab vedotin